Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multi-Center, Parallel Group Study to evaluate Efficacy and Safety of GK664S in Subjects with moderate-to-severe scalp Seborrheic dermatitis.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs GK 664S (Primary)
- Indications Seborrhoeic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Maruho
- 17 Dec 2018 New trial record